Inside the research
The Cigna Group
CI Research profile · latest available data
Price overview
$272.01
▲ +6.51 (+2.5%)
| 52w hi | $304.11 |
|---|---|
| 52w lo | $238.99 |
| Vol | 1.82M |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.33
| Short | +0.36 |
|---|---|
| Medium | +0.33 |
| Long | +0.29 |
computed 2026-09-27
Key fundamentals
The Cigna Group
Healthcare · Healthcare Plans
| Market cap | $71.88B |
|---|---|
| Enterprise value | $96.79B |
| Trailing P/E | 11.25x |
| Forward P/E | 8.14x |
| EV / EBITDA | 7.59x |
| P / S (ttm) | 0.25x |
| Profit margin | 2.3% |
| Return on equity | 16.8% |
| Revenue growth | +6.7% |
| Earnings growth | +10.2% |
| Debt / equity | 74.29 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.25 | |
| Sector | +0.08 | |
| Technical | -0.04 | |
| Earnings | +0.00 | |
| Sentiment | +0.52 |
macro × 1.00 · 2026-09-27
Business overview
The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. It operates through two segments: Evernorth Health Services and Cigna Healthcare. The Evernorth Health Services segment includes Pharmacy Benefit Services and Specialty and Care Services, offering pharmacy benefit management, drug claim adjudication, retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management, pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty pharmaceutical distribution, and clinical programs for whole-person health outcomes. The Cigna Healthcare segment comprises U.S. Healthcare and International Health, delivering comprehensive medical and coordinated solutions such as employer medical plans, individual and family plans, behavioral health, consumer health engagement, dental, pharmacy management, stop-loss insurance, global health care, and local health care solutions, as well as health care benefits for mobile individuals and employees of multinational organizations. The company offers other operations, including corporate-owned life insurance, reinsurance, and certain run-off and non-strategic businesses. The company distributes its products and services through brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Risk Metrics
| Beta vs SPX | 0.12 |
|---|---|
| Corr SPX | 0.06 |
| Annual vol | 31.2% |
| Annual ret | -8.5% |
| Sharpe | -0.27 |
| Max DD | -31.8% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $340.50 |
|---|---|
| High / Low | $378.00 / $290.00 |
| Median | $339.00 |
| Analysts | 24 |
| Strong Buy | 6 | |
|---|---|---|
| Buy | 16 | |
| Hold | 2 | |
| Sell | 0 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-05-05 | Bernstein | → Outperform |
| 2026-05-04 | Guggenheim | → Buy |
| 2026-05-01 | Wells Fargo | → Equal-Weight |
| 2026-05-01 | RBC Capital | → Outperform |
| 2026-05-01 | Cantor Fitzgerald | → Overweight |
| 2026-05-01 | Barclays | → Overweight |
Officers & Board
| Director | Neesha Hathi since 2021 |
|---|---|
| Director | George Kurian since 2021 |
| Director | Kimberly Ross since 2020 |
| Director | Elder Granger since 2018 |
| Director | Mark McClellan since 2018 |
| Director | Kathy Mazzarella since 2018 |
| Director | William J. DeLaney III since 2018 |
| Director | Eric J. Foss since 2011 |
| Director | David Cordani since 2009 |
| Director | Eric Wiseman since 2007 |
| Director | Ike Harris since 2005 |
| Director | Donna Zarcone since 2005 |
| Director | John Partridge 2009–2022 |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-07-30 | Earnings Release, Exhibits | read |
| 2026-05-13 | Reg FD Disclosure | read |
| 2026-04-30 | Earnings Release, Exhibits | read |
| 2026-04-27 | Shareholder Vote | read |
| 2026-03-03 | Officer / Director Change, Reg FD Disclosure… | read |
| 2026-02-27 | Reg FD Disclosure | read |
| 2026-02-05 | Earnings Release, Exhibits | read |
| 2025-11-18 | Other Material Event | read |
| 2025-10-30 | Earnings Release, Exhibits | read |
| 2025-10-20 | Officer / Director Change | read |
| 2025-09-04 | Material Agreement, Material Obligation… | read |
| 2025-09-02 | Reg FD Disclosure | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-05 | Jones Nicole S | See Remarks | Option exercise | 1.30K | $249.82K |
| 2026-08-04 | Jones Nicole S | See Remarks | Sell | 19.44K | $5.37M |
| 2026-08-04 | Jones Nicole S | See Remarks | Option exercise | 14.04K | $2.70M |
| 2026-06-12 | Kates Jamie G | Chief Accounting Officer | Option exercise | 899 | $137.45K |
| 2026-06-12 | Kates Jamie G | Chief Accounting Officer | Sell | 899 | $268.45K |
| 2026-06-01 | Koka Durga Prasad | EVP, Global CIO | Withheld for tax | 729 | $200.86K |
| 2026-05-13 | Cordani David | Chairman & CEO | Option exercise | 7.97K | $1.57M |
| 2026-05-13 | Cordani David | Chairman & CEO | Option exercise | 15.46K | $2.31M |
| 2026-05-12 | Cordani David | Chairman & CEO | Option exercise | 85.52K | $16.88M |
| 2026-05-12 | Cordani David | Chairman & CEO | Option exercise | 103.59K | $15.45M |
Flow & Concentration
| Insider 180d net | -$64.75M |
|---|---|
| Insider buys / sells | 0 / 15 |
| Insider bias | Sellers |
| 13F holders | 9 |
| Top-5 share | 96.0% |
| HHI | 3,740 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $3.50B | 12.68M |
| Fidelity / FMR LLC | $2.21B | 8.02M |
| AQR Capital Management | $396.03M | 1.44M |
| Citadel Advisors | $227.94M | 826.84K |
| Capital Research / Capital World | $213.80M | 775.54K |
| Millennium Management | $155.69M | 564.75K |
| Renaissance Technologies | $95.25M | 345.50K |
| Bridgewater Associates | $24.23M | 87.91K |
| T. Rowe Price Group | $348.75K | 1.27M |
As of 2026-06-30
Connections
Dividends
| Yield (TTM) | 1.13% |
|---|---|
| $ / share (TTM) | $3.07 |
| 5y CAGR | +172.8% |
Annual dividend per share
| 2021 | $4.00 |
|---|---|
| 2022 | $4.48 |
| 2023 | $4.92 |
| 2024 | $5.60 |
| 2025 | $6.04 |
| 2026 | $1.56 |
SEC Filings
The Long Run
FY 2018–2025 · 8 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $274.90B | +59.6% | |
| Operating income | $9.42B | +17.3% | |
| Cash from ops | $11.81B | +17.7% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $266.13 | $273.36 | $265.35 | $272.01 | 1.82M |
| Sep 24 | $267.90 | $269.33 | $263.76 | $265.50 | 1.61M |
| Sep 23 | $273.26 | $274.75 | $267.02 | $268.27 | 1.83M |
| Sep 22 | $276.85 | $278.47 | $272.73 | $273.74 | 1.47M |
| Sep 21 | $275.91 | $275.91 | $272.62 | $274.47 | 1.39M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →